Gem Aromatics Announces Sequential Improvements in Financial Performance and Operational Updates
Gem Aromatics Ltd., a manufacturer and exporter of essential oils and aroma chemicals, announced its un-audited financial results for the quarter and audited financial results for the Full Year ended March 31, 2026. The company, a provider of specialty ingredients and value-added derivatives, reported performance improvements driven by recovering domestic and global demand.Gem Aromatics Ltd. is a well-established player in the specialty ingredients market, with a diverse portfolio exceeding 80 products covering Mint & Mint Derivatives, Clove & Clove Derivatives, and various synthetic and natural ingredients. These products cater to industries including oral care, cosmetics, pharmaceuticals, nutraceuticals, and personal care, serving both domestic and global customers.
Financial Highlights
The company released detailed financial results for the quarter ended March 31, 2026 (Q4FY26), alongside full-year figures for FY26 and FY25.Standalone Financial Highlights (Rs Cr)
| Particulars | Q4FY26 | Q4FY25 | Q3FY26 | FY26 | FY25 |
|---|---|---|---|---|---|
| Revenue from Operations | 112.2 | 206.3 | 83.9 | 370.9 | 497.0 |
| Gross Profit | 26.2 | 59.1 | 15.4 | 74.5 | 120.0 |
| Gross Margin (%) | 23.4% | 28.7% | 18.4% | 20.1% | 24.1% |
| EBITDA | 15.1 | 48.8 | 7.6 | 39.4 | 85.8 |
| EBITDA Margin (%) | 13.4% | 23.7% | 9.1% | 10.6% | 17.3% |
| PAT | 11.9 | 35.1 | 4.2 | 26.7 | 56.9 |
| PAT Margin (%) | 10.6% | 17.0% | 5.0% | 7.2% | 11.4% |
| EPS (Rs) | 2.3 | 7.5 | 0.8 | 5.3 | 12.1 |
| Cash PAT (Depreciation + PAT) | 13.3 | 36.8 | 6.2 | 33.0 | 63.5 |
Consolidated Financial Highlights (Rs Cr)
| Particulars | Q4FY26 | Q4FY25 | Q3FY26 | FY26 | FY25 |
|---|---|---|---|---|---|
| Revenue from Operations | 110.4 | 202.2 | 78.9 | 366.5 | 504.0 |
| Gross Profit | 33.7 | 54.3 | 19.9 | 90.3 | 125.2 |
| Gross Margin (%) | 30.5% | 26.9% | 25.2% | 24.6% | 24.8% |
| EBITDA | 15.7 | 45.9 | 7.0 | 40.8 | 88.5 |
| EBITDA Margin (%) | 14.2% | 22.7% | 8.9% | 11.1% | 17.6% |
| PAT | 1.0 | 27.6 | -5.0 | 1.4 | 53.4 |
| PAT Margin (%) | 0.9% | 13.7% | -6.3% | 0.4% | 10.6% |
| EPS (Rs) | 0.2 | 5.9 | -1.0 | 0.3 | 11.4 |
| Cash PAT (Depreciation + PAT) | 10.0 | 29.5 | 3.7 | 24.0 | 60.7 |
Note: Figures are rounded off to the nearest decimal.
Key Operational and Business Highlights
The company noted that the Q4FY26 results reflected a gradual recovery in domestic and global demand, which was supported by better clarity on USA tariffs and improving trade conditions. This environment led to better volumes and improved price realization across core product categories. Non-mint derivatives, such as clove, continued to progress as part of the company's diversification strategy.The company observed that Gross Margin and EBITDA Margin improved sequentially, trending towards normalized levels. This improvement was attributed to better price realization, increasing volumes, operating leverage benefits, and a healthier product mix. Management remains focused on optimizing product mix and enhancing operational efficiencies to sustain margin performance.
Consolidated Profit After Tax (PAT) for the quarter stood at Rs 1 Cr, compared to a loss of Rs 5 Cr in the previous quarter. Cash PAT improved to Rs 10 Cr from Rs 4 Cr sequentially. Profitability was impacted by higher depreciation, following the capitalization of a significant portion of the approximately Rs 260 Cr capex for the Dahej facility, against the total planned capex of approximately Rs 270 Cr.
Corporate Updates and Milestones
Sustainability Recognition: The Silvassa plant received the Platinum Rating from EcoVadis, acknowledging the company's strong commitment to sustainable operations, responsible manufacturing, and ESG practices.Subsidiary Expansion: The wholly owned subsidiary, Krystal Ingredients Pvt. Ltd., commenced commercial production of GEM Cool 5 (Cooling Agent) and Safranal at the Dahej facility on February 26, 2026. This strengthens the integrated portfolio across cooling agents, Safranal, Clove Oil, Eugenol, and clove derivatives.
Operationally, the plant also completed second stage audits for FSSC 22000 Version 6, GHP, HACCP, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. The facility is also prepared for the production of phenol derivatives, though the company noted that geopolitical issues have increased prices of petrochemical raw materials like phenol, affecting production timelines.
Management Commentary
Yash Vipul Parekh, MD & CEO, stated that the quarter saw a meaningful improvement in the operating environment due to reduced uncertainty and better clarity on USA tariffs. He highlighted that the sequential improvement in performance was backed by better volumes, improved price realization, and stronger customer engagement.Mr. Parekh reiterated the focus on the medium-term outlook, noting that while near-term production for phenol derivatives is impacted by significant price volatility in key petrochemical raw materials, the company remains optimistic about the long-term market conditions.
Company Overview
Established in 1997, Gem Aromatics Ltd. is a leading manufacturer of specialty ingredients and aroma chemicals. The company operates three manufacturing facilities across Uttar Pradesh, Gujarat, and Daman & Diu, with an installed capacity of 16,171 MTPA.GEMAROMA Stock Price Movement
On Thursday, Gem Aromatics Limited shares edged higher, closing at ₹160.05 after gaining ₹1.05, representing a 0.66% increase. The equity saw notable trading activity, with the total volume reaching 63,179 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: